Guardant Health’s Post

For a good start this August, we launch a new article about exosomes in our blog! Did you know that in recent years, emerging research has shed light on the role of exosomes in breast cancer progression and their potential as diagnostic tools and therapeutic targets? Read the full article by clicking below.

Dive into our latest article with Labiotech, where we shine the spotlight on the groundbreaking work carried out at the Dana-Farber Cancer Institute at Harvard Medical School where researchers utilized cell avidity-tuning to ensure the safety of their CAR-T therapy for targeting solid tumors. 🔬 🎯 Dr. Yufei (Sophie) Wang and Professor Wayne Marasco’s labs developed a 'G9' CAR, meticulously engineered to precisely target kidney cancer cells with exceptional specificity, binding with high Cell Avidity. By sparing healthy cells, this breakthrough significantly reduces the risk of adverse side effects in clinical settings. This milestone not only demonstrates the efficacy of the G9 CAR but also underscores the significance of evaluating cell-cell interactions using avidity metrics. Check out the article here: https://lnkd.in/dZ6hWh97

A combination therapy is demonstrating effective results in women with ER-positive/HER2-negative metastatic breast cancer.

Learn about new approaches to CAR design and how cell avidity measurements can be used to achieve that!

CELLSEARCH® CTC count proves its clinical utility in guiding therapeutic strategy supporting patient care in HR+/HER2- metastatic breast cancer

New Selective ER Modulator Shows Promising Clinical Activity in HR-positive Metastatic Breast Cancer with ESR1 Mutation After Progression https://lnkd.in/ezR5DQVQ?

A combination therapy is demonstrating effective results in women with ER-positive/HER2-negative metastatic breast cancer.

Curious to know what led to a standing ovation by specialists during a medical congress?  That’s what happened at the ESMO congress in Madrid thanks to the extraordinary study presented by Thomas Powles. Discover how a combination of drugs has doubled survival in patients with advanced bladder cancer. The data is exciting and the prospects are promising!  🔷 Read the article in the IBSA Foundation for scientific research blog: https://lnkd.in/dHKftxi9 #IBSA #CaringInnovation #ScienceBeyondFrontiers #IBSAFoundation #oncology #sciencenews #scientificfindings

In a video interview with OncLive, Alexandra Sokolova, M.D., discusses key findings from a phase 3 clinical trial in patients with metastatic castration-resistant prostate cancer: https://lnkd.in/g9Bbjr2m #ProstateCancerAwareness